NAVIGATION

February 15, 2019
cancer
cancer
The FDA approved Keytruda for a range of cancers with a common biomarker. At right, Dr. Thomas George, associate director of clinical investigation at University of Florida Health Cancer Center.

Cancer Care

Wider Approval

The FDA takes a broader approach to approving drug therapy.

Amy Martinez | 2/27/2018

Historically, the FDA has approved cancer drugs based on a particular cancer’s location in the body, but that may be changing.

Last year, the FDA said Keytruda, a new immunotherapy drug by Merck, could be used to treat all cancers that share a genetic abnormality called mismatch repair (MMR) deficiency. It was the first time the FDA approved a cancer drug based on a common biomarker rather than the cancer type — lung vs. breast, for example. Keytruda itself previously had been approved for patients with metastatic lung, neck and skin cancers.

The immunotherapy targets proteins on T-cells that prevent a patient’s immune system from recognizing and attacking cancer cells. By blocking these proteins, Keytruda aims to increase the im- mune system’s ability to home in on cancer cells without harming normal, healthy tissue. About 40% of cancer patients who received Keytruda in clinical trials saw their tumors shrink or disappear.

Doctors estimate that 4% of all cancers are MMR deficient, potentially making 60,000 patients a year eligible for the infused drug, which costs about $150,000 a year.

“At some point in the future — and it may be past my lifetime — if the immune system can be harnessed safely and effectively, there should be no need for surgery, radiation and traditional chemotherapy,” says Dr. Thomas George, associate director of clinical investigation at University of Florida Health Cancer Center. “The cancer should be permanently destroyed by a patient’s own immune system.”

 

See other stories from Florida Trend's March issue.

Get Florida Trend's March magazine – print or digital. Select from these options:

EXISTING
DIGITAL
SUBSCRIBERS

Access Article Now!

DIGITAL
SINGLE
ISSUE

Get a single DIGITAL copy of this issue

$4.95

PRINT
SINGLE
ISSUE

Get a single PRINT copy of this issue

$4.95
plus $3 postage & handling

PRINT SUBSCRIPTION

One year in PRINT

$14.98*
plus a FREE gift!

DIGITAL SUBSCRIPTION

One year DIGITAL

$14.98*
plus a FREE gift!

ALL ACCESS SUBSCRIPTION

One year Combo
PRINT + DIGITAL

$24.95*
plus a FREE gift!


CURRENT  PRINT  SUBSCRIBERS

If you are already a print subscriber,
ADD DIGITAL EDITION ACCESS
to your existing subscription here!
(or call our office at 727-892-2643)

* offer valid for new subscribers only

Tags: Government/Politics & Law, Healthcare, Life Sciences, Research & Development, Technology/Innovation, Cancer Care, Economic Backbone

Digital Access

DIRECT DIGITAL ACCESS
Add digital to your current subscription, purchase a single digital issue, or start a new subscription to Florida Trend.

TABLE OF CONTENTS
An overview of the features and articles in this month's issue of Florida Trend.

ACCESS THIS ISSUE »

Florida Business News

Florida Trend Video Pick

Miami Yacht Show to open in its new location
Miami Yacht Show to open in its new location

The 31st Miami Yacht Show, the city’s premier luxury yacht show, takes place from February 14 -18, 2019 in its new location at One Herald Plaza. See a video of preparation for the event.

Earlier Videos | Viewpoints@FloridaTrend

Ballot Box

Have you ever been the victim of a cyber crime?

  • No
  • Yes

See Results

Ballot Box
Subscribe